Integra LifeSciences Appoints Former Siemens Healthineers Executive Dr. Raymond Turner as Chief Medical Officer

Sep 23, 2025 18:31 CST Updated 18:31

Integra LifeSciences

Comprehensive Medical Equipment Company

Johnson & Johnson

Medical Device R&D and Manufacturer

Shanghai Event Registration:2025 Medical Device R&D Innovation Forum

September 22, 2025Integra LifeSciencesAnnouncementAppointment of Dr. Raymond Turner as Vice President and Chief Medical Officer (CMO) of the Company. This neurosurgical expert, with over two decades of clinical and industry experience, will be responsible for medical affairs and clinical development on a global scale, further advancing the company's efforts in evidence-based medicine and innovative transformation.

# From the Operating Table to the Executive Suite: The Turnaround of a "Doctor-Leader"

Raymond TurnerWith over 20 years of clinical and research experience in neurosurgery. In addition toChief Medical Officer at Siemens Healthineers(In charge of the vascular interventional robotics business)之外，他还在Johnson & Johnson Cerenovus served as Medical Director, deeply involved in the clinical research and commercialization pathway of neurovascular devices.

In the academic field, Turner served as the director of the neurosurgery residency program at the Medical University of South Carolina and held the position ofDepartment of Neuroscience(Head of Neurosurgery, Neurology, and Otolaryngology) overseeing both research and education. He has long provided neurosurgical diagnosis and treatment services to patients and has recently continued his clinical practice at Intermountain Health. ThisClinical + Academic + Industry's cross-disciplinary experience has made him one of the few executives capable of seamlessly transitioning between the operating room and the boardroom.

# AboutRecent Developments of Integra

Integra LifeSciencesHeadquartered in Princeton, New Jersey, USA, with operations covering more than 100 countries and regions. The company primarily focuses on two major fields: neurosurgery and reconstructive & regenerative surgery, with core products includingArtificial Dura Mater, Craniomaxillofacial Repair Materials, Skin Substitutes, Wound Covering Products, as well as specialized surgical instruments for microsurgery and otolaryngology. With continuous investment in neurosurgical consumables and regenerative medicine materials, along with the acquisition and integration of businesses such as Codman Neurosurgery, Integra has become one of the leading companies globally in the fields of neurosurgery and tissue repair.

In addition to the appointment of medical executives, Integra has also made a series of new moves at the product and operational levels, all of which will create a compounding effect with Turner's arrival:

Business and Financial PerformanceIn the fourth quarter of 2024, the company's revenue reached approximately $442.6 million.Full-year revenue approximately USD 1.6105 billionAmong them, neurosurgery and cerebrospinal fluid management businesses have seen significant growth, with core products includingCereLink^®、Certas^®Plus and BactiSeal^®, etc. DuraSorb in the Trauma and Regeneration (Tissue Technologies) section^®、MicroMatrix^®、Cytal^®and AmnioExcel^®Also maintains a high demand in the wound reconstruction market.
Product Pipeline Expansion: The company announced at the end of 2023 to acquire for approximately US$275 millionJohnson & Johnson Subsidiary Acclarent, further strengthening the ENT and navigation system product lines. This acquisition reflects that Integra, while relying on internal R&D, is also actively improving its product portfolio through external acquisitions.
Quality and Compliance Challenges: Some product lines (such as Integra Skin) face capacity bottlenecks. To address this, the company is advancing a quality and compliance system called the Compliance Master Plan to strengthen production and supply chain stability. This means that Turner will not only need to focus on clinical and evidence-based research in the future but also demonstrate medical leadership in quality and regulatory compliance.

Overall, Turner's arrival not only strengthens the executive team but also aligns with the company's current product expansion, merger and acquisition strategy, and quality system upgrade, potentially enhancing overall competitiveness in clinical evidence, medical communication, and regulatory compliance.

# Integra's Strategic Choice: Clinical Evidence-Driven Innovation

As a global leading neuro and regenerative medicine device company, Integra has always emphasizedEvidence-Based Medicine and Clinical DataThe core role in the implementation of innovation. The appointment of Raymond Turner this time not only supplements the management team but also signals the company's future development direction to the outside world:

Strengthen Clinical Research and Trial OperationsTurner will oversee the design and execution of global clinical trials, advancing more products into high-level, multi-center validation phases.
Enhance the Accumulation of Real-World Evidence (RWE): Combining his experience at Siemens Healthineers and academic institutions, Integra is expected to systematically collect and utilize RWE in the future, supporting further proof of the product's value post-market.
Focus on Patient Safety and Efficacy: As emphasized by Integra CEO Mojdeh Poul, Turner's clinical background and leadership will help the companySafety, Efficacy, and AccessibilityBreakthroughs achieved more quickly across three dimensions.

This kind of executive configuration based on clinical logic aligns with the transformation that the industry is currently undergoing – medical device companiesShifting from "Engineering-Driven" to "Clinically-Driven"。

Conclusion

Integra Appoints Turner as Chief Medical Officer: A Strategic Move Amid Global Expansion, Product Diversification, and Evidence-Based Research AdvancementWhether it can establish long-term credibility in medical evidence, compliance systems, and clinical value。

SIYU Annual Event Review:First Global Ophthalmology Conference | The First Global Orthopedic Conference | The First Global Cardiovascular Conference| The First Global Medical Aesthetics Technology Conference |The 2nd Global Medical Technology Conference|The 3rd Global Surgical Robotics Conference